A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors

计划入组 45 人 · 首次发布于 2010 年 6 月 14 日

HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma

计划入组 33 人 · 首次发布于 2016 年 7 月 19 日

Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation

计划入组 316 人 · 首次发布于 2024 年 8 月 5 日

solid tumors therapy

CLK3 inhibitor (oral, solid tumors), Biosplice Therapeutics

CLK2 inhibitor (oral, solid tumors), Biosplice Therapeutics

Solid Biosciences Inc.

United States

Yichang Humanwell Oral Solid Dosage Plant

China

BioLine Rx

Israel

FORE Biotherapeutics Advances Plixorafenib in BRAF-Driven Tumors, Eyes Potential FDA Submission

FORE Biotherapeutics Secures $38 Million in Series D-2 Financing to Advance Plixorafenib Clinical Trials

FORE Biotherapeutics Highlights Recent Pipeline Achievements and Strategic Objectives for 2025